[DGTR tracker](https://indusdesk.com/dgtr/tracker/)

# DGTR recommends provisional duty on ethambutol hydrochloride from China and Thailand

https://indusdesk.com/dgtr/tracker/recommends-provisional-duty-on-ethambutol-hydrochloride-from-china-269765/

The Directorate General of Trade Remedies has issued preliminary findings, dated January 30, 2026, in the anti-dumping investigation into imports of Ethambutol Hydrochloride originating in or exported from China and Thailand. The investigation was initiated on September 23, 2025 on an application by Lupin Limited.

Case No. AD (OI) – 22/2025 · Preliminary findings · January 30, 2026

IndusDesk · January 30, 2026

DGTR published this on January 30, 2026 under Case No. AD (OI) – 22/2025. The Directorate General of Trade Remedies has issued preliminary findings, dated January 30, 2026, in the anti-dumping investigation into imports of Ethambutol Hydrochloride originating in or exported from China and Thailand. The investigation was initiated on September 23, 2025 on an application by Lupin Limited.

Ethambutol Hydrochloride is a bacteriostatic drug used in anti-tuberculosis medication, and the investigation covers both the hydrochloride salt and Ethambutol in free base form. The period of investigation is April 1, 2024 to March 31, 2025. Three Chinese producers or traders responded; no exporter from Thailand took part.

The Authority provisionally found dumping margins of 20-30% and 25-35% for China and 15-25% for Thailand, and injury margins of 10-20% to 15-25%. Imports rose from 16 MT in 2021-22 to 122 MT in the period of investigation, their market share reached 30-40%, and they undercut and depressed domestic prices. The domestic industry recorded losses, cash losses and negative returns while a significant portion of its capacity remained idle.

The Authority recommends provisional anti-dumping duty of US$ 5,124 per MT for Wuhan Wuyao Pharmaceutical Co. Limited, US$ 6,096 per MT for other imports from China and US$ 6,513 per MT for imports from Thailand, to be imposed by the Central Government. Interested parties may comment within 15 days of publication, and an oral hearing and disclosure of essential facts will follow before final findings.

**Measure**: Anti-dumping

**Stage**: Preliminary findings

**Case number**: Case No. AD (OI) – 22/2025

**File number**: F. No. 6/25/2025-DGTR

**Dated**: January 30, 2026

**Published in the Gazette**: January 30, 2026

**Put online**: February 2, 2026

**Gazette ID**: CG-DL-E-02022026-269765

**Product**: Ethambutol Hydrochloride

**What it covers**: Ethambutol Hydrochloride, a bacteriostatic drug with molecular formula C10H24N2O2.2HCl: a white crystalline powder made from Ethambutol, a pure compound (free base) that is converted into its hydrochloride salt for use in tablets and other dosage forms. The investigation covers the product when imported into India in both forms. No PCN methodology was adopted.

**Customs codes**: 2905 14 10, 2905 14 90

**Countries**: China, Thailand

**Applicant**: M/s Lupin Limited

**Period of investigation**: 1st April 2024 to 31st March 2025 (12 months)

**Injury period**: FY 2021-22, FY 2022-23, FY 2023-24 and the period of investigation

**Findings**:

- Lupin Limited accounts for a major proportion of eligible domestic production and constitutes the domestic industry with standing under Rule 5(3); Cadila Pharmaceuticals Limited, the other producer, imported the subject goods in the period of investigation.

- No producer or exporter from China claimed market economy treatment, so normal value for China was provisionally determined as the price payable in India, based on the domestic industry's cost of production with selling, general and administrative expenses and profits.

- No producer or exporter from Thailand cooperated, and normal value and export price for Thailand were determined on facts available under Rule 6(8); the conclusions describe the Thailand normal value as based on cost of production, selling, general and administrative expenses and reasonable profits.

- Provisional dumping margins are 20-30% for Wuhan Wuyao Pharmaceuticals Co. Limited and 25-35% for other producers in China, and 15-25% for producers in Thailand.

- Provisional injury margins are 10-20% for Wuhan Wuyao Pharmaceuticals Co., Limited and other producers in China, and 15-25% for producers in Thailand.

- Imports from the subject countries rose from 16 MT in 2021-22 to 122 MT in the period of investigation, and their market share rose from 0-10% to 30-40% while the domestic industry's share fell from 90-100% to 60-70%.

- Subject imports undercut the domestic industry's prices (range 0-10%) and depressed and suppressed its prices.

- The domestic industry suffered losses, cash losses and negative returns in the period of investigation, and a significant portion of its capacity remained idle although it can cater to the entire Indian demand.

- The Authority found that no other known factor caused injury and noted that the subject goods are used in anti-tuberculosis medication; the domestic industry claimed that the impact of anti-dumping duties on the end product would be around 0-2%.

**Recommendation**: The Authority recommends provisional anti-dumping duty equal to the lesser of the margin of dumping and the margin of injury on imports of the subject goods originating in or exported from China and Thailand, in the amounts in Col. 7 of the duty table, to be imposed by the Central Government pending completion of the investigation.

**Duty expressed as**: Amount in US$ per MT

**Time limits**: Interested parties to comment on the preliminary findings: within 15 days from the publication of these findings

**What happens next**: The Authority will hold an oral hearing under Rule 6(6), with the date to be published on the DGTR website, conduct further verification as needed, and disclose the essential facts before issuing final findings.

## The duty table

| Country | Producer | Duty |
|---|---|---|
| China PR (country of origin), exported from any country | Wuhan Wuyao Pharmaceutical Co. Limited | US$ 5,124 per MT |
| China PR (country of origin), exported from any country | Any producer other than S. No. 1 | US$ 6,096 per MT |
| Any country other than China PR and Kingdom of Thailand (country of origin), exported from China PR | Any | US$ 6,096 per MT |
| Kingdom of Thailand (country of origin), exported from any country | Any | US$ 6,513 per MT |
| Any country other than China PR and Kingdom of Thailand (country of origin), exported from Kingdom of Thailand | Any | US$ 6,513 per MT |

[The notification](https://files.indusdesk.com/dgtr/cases/ad-oi-22-2025/preliminary-findings-2026-01-30.pdf) (PDF, 1.2 MB)

Gazette of India, [CG-DL-E-02022026-269765](https://egazette.gov.in/WriteReadData/2026/269765.pdf), published January 30, 2026.

Checked against the official copy on October 20, 2026.

- [DGTR guide](https://indusdesk.com/dgtr/)

- [All DGTR notifications](https://indusdesk.com/dgtr/tracker/)
